[{"id":"d399bf26-299c-4709-84ee-4bdf85e1b0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00617708","created_at":"2021-01-18T02:17:45.723Z","updated_at":"2024-07-02T16:36:17.448Z","phase":"Phase 2","brief_title":"S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","source_id_and_acronym":"NCT00617708","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 02/25/2014","study_completion_date":" 02/25/2014","last_update_posted":"2022-02-08"},{"id":"3cf0256f-0bef-4a24-b288-c72267995e10","acronym":"","url":"https://clinicaltrials.gov/study/NCT00684983","created_at":"2021-01-18T02:33:37.670Z","updated_at":"2024-07-02T16:36:47.849Z","phase":"Phase 2","brief_title":"Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer","source_id_and_acronym":"NCT00684983","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 07/30/2008","start_date":" 07/30/2008","primary_txt":" Primary completion: 01/07/2014","primary_completion_date":" 01/07/2014","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2020-03-24"},{"id":"594ccd90-691a-4aa9-a0de-882c8c5b0c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957853","created_at":"2021-01-18T03:43:39.679Z","updated_at":"2024-07-02T16:36:47.961Z","phase":"Phase 2","brief_title":"Preoperative Treatment With Cetuximab and/or IMC-A12","source_id_and_acronym":"NCT00957853","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/17/2011","start_date":" 10/17/2011","primary_txt":" Primary completion: 08/15/2018","primary_completion_date":" 08/15/2018","study_txt":" Completion: 08/15/2018","study_completion_date":" 08/15/2018","last_update_posted":"2020-03-19"},{"id":"d1f2bba3-a066-4ab2-ade4-ee5dabc41dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00781911","created_at":"2021-01-18T02:57:16.581Z","updated_at":"2024-07-02T16:36:55.434Z","phase":"Phase 2","brief_title":"A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer","source_id_and_acronym":"NCT00781911","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGF2","pipe":"","alterations":" ","tags":["IGF1 • IGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cixutumumab (IMC A12) • octreotide acetate solution for injection"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 07/01/2011","primary_completion_date":" 07/01/2011","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2019-09-20"},{"id":"ebcb72d9-4f33-4bf8-b8a2-f84673232821","acronym":"","url":"https://clinicaltrials.gov/study/NCT01232452","created_at":"2021-01-18T04:57:21.834Z","updated_at":"2024-07-02T16:36:55.407Z","phase":"Phase 2","brief_title":"A Study in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01232452","lead_sponsor":"Eli Lilly and Company","biomarkers":" IGF1 • IGFBP3","pipe":"","alterations":" ","tags":["IGF1 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 01/01/2013","primary_completion_date":" 01/01/2013","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2019-09-20"},{"id":"8db1babf-60a4-4a8c-891a-de73990bbe97","acronym":"BATTLE-FL","url":"https://clinicaltrials.gov/study/NCT01263782","created_at":"2021-01-18T05:06:06.604Z","updated_at":"2024-07-02T16:36:59.589Z","phase":"Phase 2","brief_title":"BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer","source_id_and_acronym":"NCT01263782 - BATTLE-FL","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK fusion","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • pemetrexed • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 05/17/2011","start_date":" 05/17/2011","primary_txt":" Primary completion: 08/15/2017","primary_completion_date":" 08/15/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2019-05-15"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"},{"id":"95b9c453-8e97-4f5a-abdf-aa632ad35d9c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00728949","created_at":"2021-01-18T02:44:40.539Z","updated_at":"2024-07-02T16:37:10.242Z","phase":"Phase 2","brief_title":"A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer","source_id_and_acronym":"NCT00728949","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 08/01/2008","start_date":" 08/01/2008","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 02/01/2015","study_completion_date":" 02/01/2015","last_update_posted":"2018-06-06"},{"id":"f71419e3-ec56-43d9-8477-d9001d63eb30","acronym":"","url":"https://clinicaltrials.gov/study/NCT00503685","created_at":"2021-01-18T01:48:22.198Z","updated_at":"2024-07-02T16:37:10.264Z","phase":"Phase 2","brief_title":"Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy","source_id_and_acronym":"NCT00503685","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3","pipe":" | ","alterations":" KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1","tags":["KRAS • KIT • RAS • UGT1A1 • IGFBP2 • IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 03/01/2009","primary_completion_date":" 03/01/2009","study_txt":" Completion: 03/01/2009","study_completion_date":" 03/01/2009","last_update_posted":"2018-06-06"},{"id":"37e90df5-af6e-4285-9888-443417e0a288","acronym":"","url":"https://clinicaltrials.gov/study/NCT01182883","created_at":"2021-01-18T04:43:35.712Z","updated_at":"2024-07-02T16:37:20.233Z","phase":"Phase 1","brief_title":"A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors","source_id_and_acronym":"NCT01182883","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2010","start_date":" 07/28/2010","primary_txt":" Primary completion: 04/04/2012","primary_completion_date":" 04/04/2012","study_txt":" Completion: 04/04/2012","study_completion_date":" 04/04/2012","last_update_posted":"2017-07-02"}]